Fenwick Represents Audentes Therapeutics in Pending $3 Billion Acquisition by Astellas Pharma

Fenwick & West is representing Audentes Therapeutics, Inc. (NASDAQ: BOLD) in its pending acquisition by Astellas Pharma Inc. (TSE: 4503) at a price of $60.00 per share in cash, representing a total equity value of approximately $3 billion.

Audentes is a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases. More information about the acquisition can be obtained from the company announcement.

The Fenwick transaction team is being led by Fenwick partners Effie Toshav, Doug Cogen, David Michaels and Stefano Quintini. The team also includes associates Maureen Montgomery, Amy Zhang, Ryan Mitteness, Alice Lin, Sawyer Li, Michael Ohta, Annie Omata, Mitchell Duncombe and Alan Huang, and law clerks Jared Leung and Karin Hjorth; executive compensation and employee benefits partners Matthew Cantor and Gerald Audant and associate Corinne Nhaissi; intellectual property and technology transactions associates Jennifer Yoon, Gregory Hopewell, Sophia Chen, Pinar Bailey and Sang Kwon, and law clerk Brandon Cheung; securities litigation associate Vincent Barredo; antitrust partner Mark Ostrau; and tax partner William Skinner and associate Ora Grinberg.